In the most recent trading session, Novavax (NVAX) closed at $8.45, indicating a +0.24% shift from the previous trading day.

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

Novavax, Inc. (NASDAQ:NVAX – Free Report) – Investment analysts at Zacks Research increased their FY2025 EPS estimates for Novavax in a research note issued to investors on Tuesday ...

Novavax (NVAX) closed at $9.34 in the latest trading session, marking a +1.3% move from the prior day. The average of price targets set by Wall Street analysts indicates a potential upside of 81.6% in ...

Shares of vaccine companies fell on Tuesday after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead ...

The global vaccines market is projected to grow by $194 billion from 2025 to 2029, with an annual growth rate of nearly 23%, according to a report by Technavio. The expansion is fueled by increased ...

A number of High Street chemists and private clinics sell and administer the Pfizer Covid vaccine directly to the public. The ...

The Senate Finance Committee has voted to advance the nomination of Robert F. Kennedy Jr. to become HHS Secretary. The vote went along party lines. Sen. Bill Cassidy (R-La.), a medical doctor who had ...